Hearing impairment in MELAS: New prospective in clinical use of microRNA, a systematic review

Arianna Di Stadio, Valentina Pegoraro, Laura Giaretta, Laura Dipietro, Roberta Marozzo, Corrado Angelini

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Aim: To evaluate the feasibility of microRNAs (miR) in clinical use to fill in the gap of current methodology commonly used to test hearing impairment in MELAS patients. Material and method: A literature review was performed using the following keywords, i.e., MELAS, Hearing Loss, Hearing Impairment, Temporal Bone, Otoacustic Emission (OTOAE), Auditory Brain Response (ABR), and microRNA. We reviewed the literature and focused on the aspect of the temporal bone, the results of electrophysiological tests in human clinical studies, and the use of miR for detecting lesions in the cochlea in patients with MELAS. Results: In patients with MELAS, Spiral Ganglions (SG), stria vascularis (SV), and hair cells are damaged, and these damages affect in different ways various structures of the temporal bone. The function of these cells is typically investigated using OTOAE and ABR, but in patients with MELAS these tests provide inconsistent results, since OTOAE response is absent and ABR is normal. The normal ABR responses are unexpected given the SG loss in the temporal bone. Recent studies in humans and animals have shown that miRs, and in particular miRs 34a, 29b, 76, 96, and 431, can detect damage in the cells of the cochlea with high sensitivity. Studies that focus on the temporal bone aspects have reported that miRs increase is correlated with the death of specific cells of the inner ear. MiR - 9/9 was identified as a biomarker of human brain damage, miRs levels increase might be related to damage in the central auditory pathways and these increased levels could identify the damage with higher sensitivity and several months before than electrophysiological testing. Conclusion: We suggest that due to their accuracy and sensitivity, miRs might help monitor the progression of SNHL in patients with MELAS.

Original languageEnglish
Article number35
JournalOrphanet Journal of Rare Diseases
Volume13
Issue number1
DOIs
Publication statusPublished - Feb 21 2018

Fingerprint

MELAS Syndrome
MicroRNAs
Hearing Loss
Temporal Bone
Spiral Ganglion
Brain
Cochlea
Stria Vascularis
Auditory Pathways
Inner Ear
Cell Death
Biomarkers

Keywords

  • Auditory brain response
  • Diagnosis
  • Hearing impairment
  • Hearing loss
  • MELAS
  • microRNA
  • Otoacustic emission

ASJC Scopus subject areas

  • Genetics(clinical)
  • Pharmacology (medical)

Cite this

Hearing impairment in MELAS : New prospective in clinical use of microRNA, a systematic review. / Di Stadio, Arianna; Pegoraro, Valentina; Giaretta, Laura; Dipietro, Laura; Marozzo, Roberta; Angelini, Corrado.

In: Orphanet Journal of Rare Diseases, Vol. 13, No. 1, 35, 21.02.2018.

Research output: Contribution to journalReview article

Di Stadio, Arianna ; Pegoraro, Valentina ; Giaretta, Laura ; Dipietro, Laura ; Marozzo, Roberta ; Angelini, Corrado. / Hearing impairment in MELAS : New prospective in clinical use of microRNA, a systematic review. In: Orphanet Journal of Rare Diseases. 2018 ; Vol. 13, No. 1.
@article{a28fb34ed6c64a959d45fc41c9363abc,
title = "Hearing impairment in MELAS: New prospective in clinical use of microRNA, a systematic review",
abstract = "Aim: To evaluate the feasibility of microRNAs (miR) in clinical use to fill in the gap of current methodology commonly used to test hearing impairment in MELAS patients. Material and method: A literature review was performed using the following keywords, i.e., MELAS, Hearing Loss, Hearing Impairment, Temporal Bone, Otoacustic Emission (OTOAE), Auditory Brain Response (ABR), and microRNA. We reviewed the literature and focused on the aspect of the temporal bone, the results of electrophysiological tests in human clinical studies, and the use of miR for detecting lesions in the cochlea in patients with MELAS. Results: In patients with MELAS, Spiral Ganglions (SG), stria vascularis (SV), and hair cells are damaged, and these damages affect in different ways various structures of the temporal bone. The function of these cells is typically investigated using OTOAE and ABR, but in patients with MELAS these tests provide inconsistent results, since OTOAE response is absent and ABR is normal. The normal ABR responses are unexpected given the SG loss in the temporal bone. Recent studies in humans and animals have shown that miRs, and in particular miRs 34a, 29b, 76, 96, and 431, can detect damage in the cells of the cochlea with high sensitivity. Studies that focus on the temporal bone aspects have reported that miRs increase is correlated with the death of specific cells of the inner ear. MiR - 9/9 was identified as a biomarker of human brain damage, miRs levels increase might be related to damage in the central auditory pathways and these increased levels could identify the damage with higher sensitivity and several months before than electrophysiological testing. Conclusion: We suggest that due to their accuracy and sensitivity, miRs might help monitor the progression of SNHL in patients with MELAS.",
keywords = "Auditory brain response, Diagnosis, Hearing impairment, Hearing loss, MELAS, microRNA, Otoacustic emission",
author = "{Di Stadio}, Arianna and Valentina Pegoraro and Laura Giaretta and Laura Dipietro and Roberta Marozzo and Corrado Angelini",
year = "2018",
month = "2",
day = "21",
doi = "10.1186/s13023-018-0770-1",
language = "English",
volume = "13",
journal = "Orphanet Journal of Rare Diseases",
issn = "1750-1172",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Hearing impairment in MELAS

T2 - New prospective in clinical use of microRNA, a systematic review

AU - Di Stadio, Arianna

AU - Pegoraro, Valentina

AU - Giaretta, Laura

AU - Dipietro, Laura

AU - Marozzo, Roberta

AU - Angelini, Corrado

PY - 2018/2/21

Y1 - 2018/2/21

N2 - Aim: To evaluate the feasibility of microRNAs (miR) in clinical use to fill in the gap of current methodology commonly used to test hearing impairment in MELAS patients. Material and method: A literature review was performed using the following keywords, i.e., MELAS, Hearing Loss, Hearing Impairment, Temporal Bone, Otoacustic Emission (OTOAE), Auditory Brain Response (ABR), and microRNA. We reviewed the literature and focused on the aspect of the temporal bone, the results of electrophysiological tests in human clinical studies, and the use of miR for detecting lesions in the cochlea in patients with MELAS. Results: In patients with MELAS, Spiral Ganglions (SG), stria vascularis (SV), and hair cells are damaged, and these damages affect in different ways various structures of the temporal bone. The function of these cells is typically investigated using OTOAE and ABR, but in patients with MELAS these tests provide inconsistent results, since OTOAE response is absent and ABR is normal. The normal ABR responses are unexpected given the SG loss in the temporal bone. Recent studies in humans and animals have shown that miRs, and in particular miRs 34a, 29b, 76, 96, and 431, can detect damage in the cells of the cochlea with high sensitivity. Studies that focus on the temporal bone aspects have reported that miRs increase is correlated with the death of specific cells of the inner ear. MiR - 9/9 was identified as a biomarker of human brain damage, miRs levels increase might be related to damage in the central auditory pathways and these increased levels could identify the damage with higher sensitivity and several months before than electrophysiological testing. Conclusion: We suggest that due to their accuracy and sensitivity, miRs might help monitor the progression of SNHL in patients with MELAS.

AB - Aim: To evaluate the feasibility of microRNAs (miR) in clinical use to fill in the gap of current methodology commonly used to test hearing impairment in MELAS patients. Material and method: A literature review was performed using the following keywords, i.e., MELAS, Hearing Loss, Hearing Impairment, Temporal Bone, Otoacustic Emission (OTOAE), Auditory Brain Response (ABR), and microRNA. We reviewed the literature and focused on the aspect of the temporal bone, the results of electrophysiological tests in human clinical studies, and the use of miR for detecting lesions in the cochlea in patients with MELAS. Results: In patients with MELAS, Spiral Ganglions (SG), stria vascularis (SV), and hair cells are damaged, and these damages affect in different ways various structures of the temporal bone. The function of these cells is typically investigated using OTOAE and ABR, but in patients with MELAS these tests provide inconsistent results, since OTOAE response is absent and ABR is normal. The normal ABR responses are unexpected given the SG loss in the temporal bone. Recent studies in humans and animals have shown that miRs, and in particular miRs 34a, 29b, 76, 96, and 431, can detect damage in the cells of the cochlea with high sensitivity. Studies that focus on the temporal bone aspects have reported that miRs increase is correlated with the death of specific cells of the inner ear. MiR - 9/9 was identified as a biomarker of human brain damage, miRs levels increase might be related to damage in the central auditory pathways and these increased levels could identify the damage with higher sensitivity and several months before than electrophysiological testing. Conclusion: We suggest that due to their accuracy and sensitivity, miRs might help monitor the progression of SNHL in patients with MELAS.

KW - Auditory brain response

KW - Diagnosis

KW - Hearing impairment

KW - Hearing loss

KW - MELAS

KW - microRNA

KW - Otoacustic emission

UR - http://www.scopus.com/inward/record.url?scp=85042354763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042354763&partnerID=8YFLogxK

U2 - 10.1186/s13023-018-0770-1

DO - 10.1186/s13023-018-0770-1

M3 - Review article

AN - SCOPUS:85042354763

VL - 13

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

SN - 1750-1172

IS - 1

M1 - 35

ER -